ONCAlert | 2018 ASCO Annual Meeting

Current Progress and Future With Glembatumumab Vedotin in TNBC

Linda T. Vehdat, MD, PhD
Published Online: 9:02 PM, Thu November 10, 2016

Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the current progress being made with glembatumumab vedotin in triple-negative breast cancer (TNBC) and what the future holds for this agent.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.